Autonomix Medical, Inc. · NASDAQ:AMIX
Autonomix Medical — Investor Presentation (November 2026)
17 slides from Autonomix Medical's investor presentation, Nov 20, 2026

Slide 1: Investor Presentation
NASDAQ: AMIX Investor Presentation November 2028

Slide 2: Forward-Looking Statements
AUTONOMIX NASDAQ: AMIX Forward-Looking Statements [AL sutamentscontonoa heen o2ter then ststements of stone feet, lung statoments Fegurng ou uur esU of epertons end Manca poston. ou business stotog ae plans, ad our eboctvs for future operations Fe frwaréSooking stent: The words “bot,” “may” “wil” ex

Slide 3: Unleashing the Power of Treatments
Unleashing the Power of Treatments Transforming minimally invasive transvascular technology to treat neurological diseases. Extensive IP Portfolio with 120+ Patents Issued and Pending High Sensitivity to Detect ang Differentiate Neural Signals, Enabling Real-Time, High Resolution Signal Capture Thro

Slide 4: The Problem
AUTONOMIX NASDAQ: AMIX The Problem Current Technologies Cannot Precisely Target and Treat Overactive Nerves. @ Current cardiac sensing technologies cannot detect low amplitude neuronal signals Senses (or maps) 100nV activity while neuronal signaling through the vessel wall is much lower, typically l

Slide 5: Illuminating the Nervous System with Transvascular Precision-Guided Technology
QLAMIx AUTONOMIX |luminating the Nervous System with Transvascular Precision-Guided Technology >

Slide 6: Enabling Sense, Treat and Verify
AuToNomix NASDAQ: AMIX Enabling Sense, Treat and Verify. Potential to Improve Patient 01 Through i ision-Guided Tr Sense (Identify) @ Treat (Ablate) @) Verify (Confirm) Overactive Nerves Target Nerves Treatment Precision Meping of Neural Advanced Ablation Catheter Immediate intre-Procedure ‘Acti to

Slide 7: Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments
AUTONOMIX NASDAQ: AMIX Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments Summary + <5} High Sensitivity to Detect and Differentiate Neural Signal Strength ‘ASIC-Powered!' Proprietary Sensory Microchip Processes Signal at the Source + Signal Travels Only Millimeters ~ Preserving Sig

Slide 8: PoC Study: First-in-Human Proof-of-Concept
PoC 1 Study: First-in- Human Proof-of-Concept Study in Pain Associated With Pancreatic Cancer PoC 1 Initial Phase and Demonstrated Statistically Number of Subje y o ry Endp. : Patients Clinical sit

Slide 9: PoC Study: Met Efficacy and Safety Objectives
AUTONOMIX NASDAQ: AMIX PoC 1 Study: Met Efficacy and Safety Objectives 100% of patients (n=16) with femoral access responded to estment® Pain relief occurred ‘Long-lasting, durable pa 100% of responders Required Zero Opioid use at $-months post-procedure 77% improvement in global quality of health '

Slide 10: Pain Reduction at 4-6 Weeks & Months
Pain Reduction at 4-6 Weeks & 3 Months PANCREATIC CANCER PAIN PoC 1 STUDY: RESPONDING FEMORAL PATIENTS MEAN VAS SCORE OVER TIME ning Post-Procedure 7 Days Follow-Up fours) (+48 Hours)

Slide 11: PoC Study: Subgroup Analysis Shows Pain Relief Across All Disease Stages
AUTONOMIX NASDAQ: AMIX PoC 1 Study: Subgroup Analysis Shows Pain Relief Observed Across All Disease Stages ‘Among ate-stag (Stage 4 cancer pti Across all disease stages, responding patients presenting with severe baseline pain Late-Stage Improvement tralia with rmna cdiassseepona Rapid Onset experie

Slide 12: PoC Study: Follow-On Expansion Protocol
avronomix NASDAQ: AMIX PoC 2 Study: Follow-On Expansion Protocol of Proof-of-Concept Study Evaluation of pain management in additional visceral cancers, earlier stagelpancreatic cancer and procedural protocol of Autonomix Sensing & RF Ablation Catheters ent to Interventional Pancreatic in Management

Slide 13: Path to Potential FDA Clearance
AUTONOMIX NASDAQ: AMIX Path to Potential FDA Clearance 2025 > 2028 IDE Clinical FDA De Novo Pocstudies |! Triaisinus P| Submission > FDA Clearance Revenue Generation Mo eg Ub Capital Expenditure Catheter Disposables del Annual Software License

Slide 14: Proof-of-Concept in Lead Indication
Proof-of-Concept in Lead Indication Opens Tot Me

Slide 15: Proven Team with Multiple Successful Exits
AUTONOMIX NASDAQ: AMIX Proven Team with Multiple Successful Exits

Slide 16: Investment Highlights
Investment Highlights NASDAQ: AMIX Transforming the diagnosis and treatment of pain and diseases of the nervous system. AUTONOMIX Approximately $8.6! incash and 3,096,437 shares outstanding as of Unleashing the Power of November 20, 2026; cash expected to fund operations into, but not beyond, Nerve-

Slide 17: Investor / Media Relations
7 ‘ONOMIX Investor / Media Relations soantors autonomix.com
Source: SEC EDGAR · 8-K filed Nov 20, 2026
More decks from Autonomix Medical, Inc.
Investor Presentation (January 2026)17 slides · Jan 9, 2026
Investor Presentation (April 2025)18 slides · Apr 30, 2025
Investor Presentation (January 2025)18 slides · Jan 22, 2025
Corporate Update (June 2024)13 slides · Jun 18, 2024
Investor Presentation (March 2024)23 slides · Mar 4, 2024
Reset Pharma — Investor Presentation (August 2023)36 slides · August 2023